Key Insights

Highlights

Success Rate

82% trial completion

Published Results

61 trials with published results (22%)

Research Maturity

168 completed trials (61% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

13.0%

36 terminated out of 277 trials

Success Rate

82.4%

-4.1% vs benchmark

Late-Stage Pipeline

20%

56 trials in Phase 3/4

Results Transparency

36%

61 of 168 completed with results

Key Signals

61 with results82% success36 terminated

Data Visualizations

Phase Distribution

211Total
Not Applicable (44)
Early P 1 (2)
P 1 (51)
P 2 (58)
P 3 (44)
P 4 (12)

Trial Status

Completed168
Terminated36
Unknown35
Recruiting18
Withdrawn8
Not Yet Recruiting5

Trial Success Rate

82.4%

Benchmark: 86.5%

Based on 168 completed trials

Clinical Trials (277)

Showing 20 of 20 trials
NCT07440225Phase 2RecruitingPrimary

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

NCT05637255Phase 2Completed

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

NCT06635148Phase 2Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06779773Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

NCT07496567Phase 2Not Yet RecruitingPrimary

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT07497815Not Yet RecruitingPrimary

Artificial Intelligence-assisted Diagnosis in Ophthalmology

NCT05439759Not ApplicableActive Not Recruiting

Factors in Learning And Plasticity: Healthy Vision

NCT05454124Not ApplicableRecruiting

Factors in Learning And Plasticity: Macular Degeneration

NCT04567303Phase 1Active Not RecruitingPrimary

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

NCT04008121Early Phase 1Recruiting

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT03846193Phase 1Terminated

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

NCT07367282Phase 4Not Yet RecruitingPrimary

Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration

NCT04762368Not ApplicableRecruitingPrimary

Learning Study: Improving Vision in Adults With Macular Degeneration

NCT07085533Recruiting

Natural History Study of Inherited Retinal Diseases

NCT00527475Phase 2CompletedPrimary

Ranibizumab and Reduced Fluence PDT for AMD

NCT05839041Phase 2Active Not Recruiting

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT05456581Not ApplicableCompletedPrimary

Scotoma Perimetry Oculomotor Training

NCT04435366Phase 3Completed

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

NCT07216924Not ApplicableNot Yet RecruitingPrimary

Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss

NCT05797896Active Not Recruiting

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

Scroll to load more

Research Network

Activity Timeline